University of Michigan Rogel Cancer Center member Arul Chinnaiyan, M.D., Ph.D. has received an Outstanding Investigator Award from the National Cancer Institute, which provides $6.5 million in funding over seven years. The grant will fund research to create new bioinformatics resources and identify new cancer biomarkers to improve diagnosis and ultimately to develop new targeted therapies.
The Rogel Cancer Center was 15th (tied with Siteman Cancer Center) in the nation for cancer care by US News and World Report "Best Hospitals" rankings for 2018-19, an honor that measures excellence in patient care. Michigan Medicine, the academic medical center of the University of Michigan, also had 10 surgical and medical specialties ranked in the nation’s top 10. The annual rankings placed Michigan Medicine No. 1 in Michigan.
The biggest threat cancer poses happens when it spreads throughout the body -- and when it has spread to the lining of the abdominal cavity it's particularly tricky. Once these advanced cancers have entered that area, they’re notoriously difficult to treat. Surgery alone is rarely successful, and traditional chemotherapy yields limited results, but a treatment called HIPEC offers hope.
Michigan Medicine and the American Australian Asian Adrenal Alliance: International Collaboration to Study Adrenal Disorders
U-M is a leader in benign adrenal disorders which include primary aldosteronism (discovered by U-M endocrinologist Jerome Conn), hypercortisolism, and pheochromocytoma/paraganglioma (excess production of adrenaline). For many years, there has been a desire to bring together a large network of institutions to work collaboratively to study adrenal disorders in a manner unable to be accomplished by single institutions or by using existing large national databases.
Researchers have identified a gene that when inhibited or reduced, in turn, reduced or prevented human non-small cell lung cancer tumors from growing. When mice were injected with non-small cell lung cancer cells that contained the gene NOVA1, three of four mice formed tumors. When the mice were injected with cancer cells without NOVA1, three of four mice remained tumor-free.
The National Cancer Institute has awarded the University of Michigan Rogel Cancer Center a grant worth $33.4 million over five years. At the same time, the center’s designation as a “comprehensive cancer center” was renewed.
New research by Max Wicha, M.D., director of the Forbes Institute for Cancer Discovery, helps explain why stem cells become resistant to cancer treatment and opens a clever new way to go after them
A new study finds many breast cancer patients are concerned about the financial impact of their diagnosis and treatment, and that they feel their doctor’s offices are not helping with these concerns.
New research shows how to personalize the lung cancer screening decision for every patient. The results could help doctors fine-tune their advice to patients so that it’s based not only on a patient’s individual lung cancer risk and the potential benefits and harms of screening, but also the patient’s attitude about looking for problems and dealing with the consequences
A new Center of Excellence for Cancer Immunology and Immunotherapy (CECII) within the Rogel Cancer Center will widen U-M’s scope of cancer immunological clinical research, positioning the institution as a global leader in this hot area of cancer research.